Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Glatman-Freedman, Aharona ; Hershkovitz, Yael ; Dichtiar, Rita ; Rosenberg, Alina ; Keinan-Boker, Lital ; Bromberg, Michal
• Description:
  We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.
• Subjects:
  BNT162 Vaccine Child COVID-19 Humans SARS-CoV-2 Vaccines
• Source:
  Emerg Infect Dis. 2023; 29(4):771-777
• Pubmed ID:
  36863005
• Pubmed Central ID:
  PMC10045694
• Document Type:
  Journal Article
• Place as Subject:
  Israel
• Volume:
  29
• Issue:
  4
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:79c76dcdfb55d22992457243ff7734fcfa780801804a35538ac4744820223423
• Download URL:
  https://stacks.cdc.gov/view/cdc/127656/cdc_127656_DS1.pdf
• File Type:
  [PDF - 1.07 MB ]